Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain
September 22, 2015 4:05 PM EDT
-Pain intensity through 24 hours reduced by 69%
-Pain
intensity through 72 hours reduced by 40%
-Time to first use
of opiate rescue medication increased by 488%
-32% of
patients received no opiate rescue through 72 hours compared to 5% for
placebo
Conference call and webcast at 8:30 am ET on September 23
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (NASDAQ:... More
